Literature DB >> 11796312

Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle.

Yuhong Qiu1, Patricia Kraft, Elizabeth C Craig, Xiulin Liu, Donna Haynes-Johnson.   

Abstract

OBJECTIVES: To identify the phosphodiesterase (PDE) isoenzymes in the rabbit detrusor and to evaluate their roles in regulating detrusor muscular tone. Cyclic nucleotides are important secondary messengers involved in modulating the contractility of various smooth muscles. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are synthesized by their respective cyclases and degraded by various PDEs.
METHODS: PDE isoenzymes from male and female rabbit detrusor were isolated by the Mono-Q anion exchange column and identified with various inhibitors. Detrusor strips from both sexes were precontracted with carbachol and relaxed with PDE inhibitors and adenylate and guanylyl cyclase activators in a tissue bath. Cyclic nucleotide concentrations in strips from male rabbits were determined after the compound treatment.
RESULTS: Similar results were obtained from both sexes in the experiments in which both sexes were used. The activities of PDE1, 2, 3, 4, and 5 were identified. Forskolin induced a dramatic rise in the cAMP levels and was the most effective relaxant. Papaverine generated moderate increases in the cAMP and cGMP levels and induced very good relaxation. Vinpocetine produced no detectable changes in the cyclic nucleotide levels but elicited good relaxation. Sildenafil caused an increase in the cGMP levels and had a similar relaxation effect as vinpocetine. Sodium nitroprusside induced some increase in cGMP and had no relaxation effect. Rolipram raised the cAMP levels significantly, yet had a moderate effect on relaxation.
CONCLUSIONS: Our results demonstrated the presence of PDE1 through 5 in rabbit detrusor muscle and supported their involvement in regulating detrusor muscle tone. The relaxation of rabbit detrusor was mainly mediated by the cAMP pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796312     DOI: 10.1016/s0090-4295(01)01471-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

1.  Selective inhibition of phosphodiesterase 1 relaxes urinary bladder smooth muscle: role for ryanodine receptor-mediated BK channel activation.

Authors:  Wenkuan Xin; Rupal P Soder; Qiuping Cheng; Eric S Rovner; Georgi V Petkov
Journal:  Am J Physiol Cell Physiol       Date:  2012-09-19       Impact factor: 4.249

2.  Inhibition of phosphodiesterases relaxes detrusor smooth muscle via activation of the large-conductance voltage- and Ca²⁺-activated K⁺ channel.

Authors:  Wenkuan Xin; Qiuping Cheng; Rupal P Soder; Georgi V Petkov
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-08       Impact factor: 4.249

3.  Phosphodiesterase1 inhibitor "Vinpocetine" ameliorates the inflammation, apoptosis and oxidative stress induced by cyclophosphamide in urinary bladder: an experimental study.

Authors:  Rehab Sabri Abdelrahman; Eman Mohamad El Nashar; Mansour Abdullah Alghamdi; Khulood Mohammed Al-Khater; Reham Ismail Taha
Journal:  Int Urol Nephrol       Date:  2022-07-11       Impact factor: 2.266

4.  Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.

Authors:  Irina V Zabbarova; Youko Ikeda; Mark G Kozlowski; Pradeep Tyagi; Lori A Birder; Basu Chakrabarty; Subashan Kpg Perera; Rajiv Dhir; Adam C Straub; Peter Sandner; Karl-Erik Andersson; Marcus J Drake; Christopher H Fry; Anthony J Kanai
Journal:  J Pathol       Date:  2022-02-15       Impact factor: 9.883

5.  Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.

Authors:  Seiji Matsumoto; Tadashi Hanai; Hirotsugu Uemura
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

Review 6.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

7.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 8.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia.

Authors:  Esref O Guven; Mevlana D Balbay; Kilciler Mete; Ege C Serefoglu
Journal:  Int Urol Nephrol       Date:  2008-07-22       Impact factor: 2.370

Review 10.  Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review.

Authors:  Silvia Joseph; Steffi A Maria; Jacob Peedicayil
Journal:  Curr Ther Res Clin Exp       Date:  2022-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.